A study of more than 600,000 U.S. veterans found that semaglutide and similar GLP-1 weight loss drugs reduced the likelihood of developing substance use disorders across multiple addiction categories. The observational analysis linked prescription records to downstream diagnosis patterns.
GLP-1 medications were developed primarily for diabetes and obesity but have shown pleiotropic effects in emerging research. Veterans Affairs databases provide large longitudinal cohorts suitable for detecting associations across diverse patient populations.
Reduced addiction risk spanned several substance categories in the study, suggesting a broad neurobiological or behavioral mechanism rather than a single-drug effect. Researchers cautioned that observational designs cannot fully establish causation without randomized trials.
The findings intersect with public health efforts to address overlapping epidemics of obesity and substance misuse. Clinicians are increasingly attentive to metabolic therapies that may influence brain reward pathways.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/